Abstract
To investigate the functional and morphologic prognoses of eyes with subfoveal hemorrhage from acute branch retinal vein occlusion (BRVO), and to examine the effect of intravitreal ranibizumab injection (IVR) on these prognoses, we assessed 81 eyes with acute BRVO, of which 38 did not receive IVR [IVR(-) group], and 43 were treated with IVR [IVR(+) group] for macular edema. The foveal morphologic changes were examined via optical coherence tomography (OCT). At initial examination, 63 eyes exhibited subfoveal hemorrhage. At final examination, the defect lengths in the foveal external limiting membrane (ELM) and ellipsoid lines in these eyes were longer, and final VA was significantly poorer, compared with eyes without subfoveal hemorrhage. In comparisons between the final measurements in eyes with subfoveal hemorrhage in the IVR(-) and IVR(+) groups, while there were no differences in initial ocular conditions, final VA was significantly better in the IVR(+) group. The defects in the ELM and ellipsoid lines in the IVR(+) group were shorter than those of the IVR(-) group (p = 0.002 in both). Final VA was correlated with the defect lengths of foveal ELM and ellipsoid lines in both the IVR(-) and IVR(+) groups (both p < 0.001). In addition, the defect lengths of foveal ELM and ellipsoid lines were closely correlated with the duration of subfoveal hemorrhage (both p < 0.001). BRVO-associated subfoveal hemorrhage caused damage to the foveal photoreceptors, and visual dysfunction. However, IVR improved these prognoses, by accelerating the absorption of the subfoveal hemorrhage.
Highlights
IntroductionAcute branch retinal vein occlusion (BRVO) often accompanies macular edema (ME), serous retinal detachment, or retinal ischemia, and some of these features may lead to impaired visual function.[1,2,3,4] Anti-vascular endothelial growth factor (VEGF) agents, including ranibizumab, cause the rapid reduction of ME associated with BRVO, and can contribute to an improvement in visual acuity (VA).[5,6,7,8] In recent studies involving optical coherence tomography (OCT), visual function has reportedly been strongly correlated with the integrityPLOS ONE | DOI:10.1371/journal.pone.0144894 December 14, 2015Foveal Damage Due to SFH after BRVO funding was received for this study
To investigate the impact of subfoveal hemorrhage on foveal functional and morphologic prognoses, and to test the hypothesis against the effect of anti-vascular endothelial growth factor (VEGF) agents on these prognoses, we studied 81 consecutive patients with or without subfoveal hemorrhage associated with acute branch retinal vein occlusion (BRVO)
The association of serous retinal detachment with visual prognosis is controversial Ohashi et al have reported that eyes with serous retinal detachment from BRVO had poor visual prognoses.[22]
Summary
Acute branch retinal vein occlusion (BRVO) often accompanies macular edema (ME), serous retinal detachment, or retinal ischemia, and some of these features may lead to impaired visual function.[1,2,3,4] Anti-vascular endothelial growth factor (VEGF) agents, including ranibizumab, cause the rapid reduction of ME associated with BRVO, and can contribute to an improvement in visual acuity (VA).[5,6,7,8] In recent studies involving optical coherence tomography (OCT), visual function has reportedly been strongly correlated with the integrityPLOS ONE | DOI:10.1371/journal.pone.0144894 December 14, 2015Foveal Damage Due to SFH after BRVO funding was received for this study. Acute branch retinal vein occlusion (BRVO) often accompanies macular edema (ME), serous retinal detachment, or retinal ischemia, and some of these features may lead to impaired visual function.[1,2,3,4] Anti-vascular endothelial growth factor (VEGF) agents, including ranibizumab, cause the rapid reduction of ME associated with BRVO, and can contribute to an improvement in visual acuity (VA).[5,6,7,8] In recent studies involving optical coherence tomography (OCT), visual function has reportedly been strongly correlated with the integrity. Foveal Damage Due to SFH after BRVO funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
